Bachem Holding AG (BANB) AI Stock Analysis

• Market Cap: CHF4.03B
• Dividend Yield: 1.72%
• Average Volume (3M): 109.83K
• Price to Earnings (P/E): 30.0
• Beta (1Y): 1.11
• Revenue Growth: 17.34%
• EPS Growth: 18.15%
• Country: CH
• Employees: 2,207
• Sector: Healthcare
• Sector Strength: 45
• Industry: Chemicals
• EPS (TTM): 0.67
• Shares Outstanding: 75,000,000
• 10 Day Avg. Volume: 97,857
• 30 Day Avg. Volume: 109,830
• PEG Ratio: 5.42
• Price to Book (P/B): 3.12
• Price to Sales (P/S): 7.17
• P/FCF Ratio: -31.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF67.43
• Price Target Upside: 36.39% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: CHF58.00 ▲(17.31% Upside)

Bachem Holding AG's strong financial performance is the most significant factor, supported by robust revenue growth and a solid balance sheet. However, technical analysis indicates bearish momentum, and the valuation suggests the stock may be overvalued. The absence of earnings call data and corporate events limits additional insights.

Bachem Holding AG Business Overview & Revenue Model

Company Description

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

How the Company Makes Money

Bachem generates revenue primarily through the sale of its peptide and oligonucleotide products, which are utilized by pharmaceutical companies in drug development and production. The company's revenue model is based on long-term contracts with clients for custom synthesis services, as well as the sale of standard peptide products. Key revenue streams include bulk sales of therapeutic peptides, contract manufacturing services, and royalties from patented products. Significant partnerships with major pharmaceutical firms enhance its market position and contribute to its earnings, as these collaborations often lead to large-scale production agreements and increased demand for Bachem's innovative solutions.

Bachem Holding AG Financial Statement Overview

Summary

Bachem Holding AG demonstrates strong financial performance with consistent revenue growth, stable gross profit margins, and healthy net profit margins. The balance sheet is robust with low leverage and a strong equity base. Cash flow from operations is strong, although high capital expenditures have impacted free cash flow.

Income Statement

Bachem Holding AG has shown a strong revenue growth rate with revenues increasing consistently year over year. The gross profit margin is stable, indicating good control over production costs. Net profit margins are healthy, supported by increasing net income over the past few years. EBIT and EBITDA margins are strong, showcasing efficient operations. The company has demonstrated solid growth and profitability in the medical pharmaceuticals sector.

Balance Sheet

The company maintains a low debt-to-equity ratio, reflecting low leverage and financial stability. The return on equity is robust, indicating effective use of equity to generate profits. The equity ratio is high, underscoring a strong capital structure. Bachem has increased its total assets significantly, primarily funded by equity, which reduces potential risks associated with high leverage.

Cash Flow

Bachem Holding AG exhibits strong operating cash flow relative to net income, indicating effective cash generation from operations. However, the free cash flow has been negative recently due to high capital expenditures, which could limit liquidity in the short term. Despite this, the company's investment in growth seems to be strategically driven.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	677.93M	605.26M	577.32M	531.74M	503.23M	402.00M
Gross Profit	211.69M	182.56M	176.96M	171.28M	166.73M	128.91M
EBITDA	190.52M	178.76M	163.28M	160.54M	156.47M	122.58M
Net Income	134.19M	120.25M	111.86M	100.68M	114.68M	78.06M
Balance Sheet
Total Assets	1.91B	1.92B	1.68B	1.38B	1.30B	710.88M
Cash, Cash Equivalents and Short-Term Investments	29.14M	95.20M	298.53M	268.43M	442.36M	23.50M
Total Debt	60.87M	290.00K	401.00K	691.00K	20.86M	107.55M
Total Liabilities	550.82M	531.88M	362.36M	214.21M	177.50M	235.17M
Stockholders Equity	1.36B	1.39B	1.32B	1.17B	1.12B	475.71M
Cash Flow
Free Cash Flow	-118.94M	-138.30M	-18.54M	-49.76M	-19.66M	45.53M
Operating Cash Flow	144.66M	146.32M	249.86M	92.59M	97.16M	114.63M
Investing Cash Flow	-172.39M	-148.88M	-170.81M	-63.17M	-469.13M	-69.31M
Financing Cash Flow	-5.30M	-61.26M	48.69M	-86.93M	437.58M	-42.66M

Bachem Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 49.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Negative. The current price of 49.44 is below the 20-day moving average (MA) of 52.89, below the 50-day MA of 56.62, and below the 200-day MA of 56.56, indicating a bearish trend. The MACD of -2.22 indicates Positive momentum. The RSI at 31.04 is Neutral, neither overbought nor oversold. The STOCH value of 17.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:BANB.

Bachem Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LONN	71 Outperform	CHF36.90B	50.96	―	0.76%	5.93%	29.83%
YPSN	70 Outperform	CHF4.49B	23.18	27.15%	0.67%	27.63%	160.67%
GALE	70 Outperform	CHF4.36B	22.68	―	2.60%	5.84%	8.57%
BANB	64 Neutral	CHF4.03B	30.01	10.07%	1.72%	17.34%	18.15%
SFZN	63 Neutral	$3.43B	21.56	15.79%	0.53%	0.77%	16.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PPGN	49 Neutral	CHF810.92M	-24.76	―	―	12.03%	-19.29%

Bachem Holding AG Corporate Events

Bachem Appoints Anne-Kathrin Stoller as New CEO

Bachem Holding AG has announced the appointment of Anne-Kathrin Stoller as the new CEO, effective January 1, 2026. Stoller, who has been with the company since 2006 and previously led Bachem Americas, succeeds Thomas Meier, who has significantly contributed to the company’s growth and innovation in the pharmaceutical industry. This leadership change is expected to continue Bachem’s successful trajectory as a globally leading developer and manufacturer of peptides and oligonucleotides.

The most recent analyst rating on (CH:BANB) stock is a Hold with a CHF61.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.

Bachem Advances Capacity Expansion with Key Milestones in Switzerland and the USA

Bachem Holding AG has reached a significant milestone in its capacity expansion plans with the inspection of Building K at its Bubendorf site, ensuring no delays in its development timeline. Additionally, the acquisition of property adjacent to its Vista, California site will bolster its production capabilities in the US, with plans to invest around USD 250 million from 2026 to 2030, enhancing its position in the global healthcare market.

The most recent analyst rating on (CH:BANB) stock is a Hold with a CHF61.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.

Bachem Appoints Hans Van Hees as New COO to Strengthen Global Operations

Bachem Holding AG has announced the appointment of Hans Van Hees as the new Chief Operations Officer (COO) and member of the Executive Committee, effective September 1, 2025. This strategic move aims to enhance Bachem’s global production network, following significant progress in its operations and capacity expansions under CEO Thomas Meier’s interim leadership as COO. Hans Van Hees brings extensive experience from his previous roles at Johnson & Johnson and Janssen, which is expected to further strengthen Bachem’s industry positioning.

The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF77.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.